专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

US20200262885A1 SELECTIVE GLUCAGON RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING PURPOSES 审中-公开
公开(公告)号：US20200262885A1
公开(公告)日：2020-08-20
申请号：US16061421
申请日：2016-12-12
申请人： SANOFI
发明人： Torsten HAACK , Oliver PLETTENBURG , Andreas EVERS , Michael WAGNER , Martin BOSSART , Romain BETRAND
IPC分类号： C07K14/605 , C07K14/575 , A61P3/10
摘要： The present invention relates to exendin-4 peptide analogues which selectively bind and activate the glucagon receptor and comprise a chelating moiety capable of binding a metal ion and their use, for example in PET imaging.

52. 发明申请

US20200255492A1 LEPTIN PEPTIDES AND THEIR USE FOR TREATING NEUROLOGICAL DISORDERS 审中-公开
公开(公告)号：US20200255492A1
公开(公告)日：2020-08-13
申请号：US16642627
申请日：2018-08-30
申请人： UNIVERSITY OF DUNDEE , UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS
发明人： Jenni HARVEY , Gayle DOHERTY
IPC分类号： C07K14/575 , A61P25/28
摘要： A method of treating a neurological disorder comprising administering a leptin peptide fragment comprising amino acids located within the region of amino acids 116-125 of leptin is disclosed. The leptin peptide fragment preferably comprises up to 30 amino acids, and/or wherein the leptin peptide fragment comprises one or more amino acids located between amino acids 116-122 of leptin, for example the sequence X1CX2LPX3X4 wherein X1 is selected from G or S; X2 is selected from S, H or P; X3 is selected from Q, H, W, L, P or R and X4 is selected from T, A, or V (SEQ ID NO:14) or the sequence SCHLPWASGL (SEQ ID NO:22). The neurological disorder can include those which would benefit from treatment through cognitive enhancement and/or neuroprotection, such as age-associated memory impairment or loss, mild cognitive impairment, and Alzheimer's disease, and can include Parkinson's disease, frontotemporal dementia, progressive supranuclear palsy, Pick's disease, corticobasal degeneration, alcoholic dementia, (DLB) dementia with Lewy bodies, Picks' disease, thalamic dementia, hippocampal sclerosis, Hallervorden-Spatz, multiple system atrophy, tauopathies, subacute aterioscleroitic encephalopathy (Binswanger's disease), amyloid angiopathy, vasculitis, prion diseases, and paraneoplastic syndromes. The invention also includes a pharmaceutical formulation for this method, which can include the peptide in the form of a cyclic peptide or a peptide conjugate.

53. 发明授权

US10738110B2 PAC1 antibodies and uses thereof 有权
公开(公告)号：US10738110B2
公开(公告)日：2020-08-11
申请号：US16246326
申请日：2019-01-11
申请人： AMGEN INC.
发明人： Neeraj Jagdish Agrawal , Kevin Graham , Agnes Eva Hamburger , Christopher Mohr , Derek E. Piper , Kenneth William Walker , Zhulun Wang , Cen Xu
IPC分类号： C07K16/00 , A61K39/395 , A61K39/00 , C12P21/08 , A61K49/00 , A61K49/16 , G01N33/53 , C07K16/18 , C07K16/28 , A61P25/06 , A61K38/22 , A61K47/68 , A61K38/17 , A61K51/10 , C07K14/575 , C07K16/26 , C07K14/72 , C07K14/47 , G01N33/74 , G01N33/68
摘要： The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

54. 发明申请

US20200247864A1 COMBINATORIAL GENE CONSTRUCT AND NON-VIRAL DELIVERY FOR ANTI-OBESITY 审中-公开
公开(公告)号：US20200247864A1
公开(公告)日：2020-08-06
申请号：US15776067
申请日：2016-03-25
申请人： UNIVERSITY OF UTAH RESEARCH FOUNDATION
发明人： You Han Bae , Hongsuk Park , Sungpil Cho
IPC分类号： C07K14/575 , C07K14/78 , C12N9/64 , C12N5/071
摘要： The invention provides a plasmid comprising two or more anti-obesity genes. Also provided by the invention are compositions and host cells comprising the plasmid and methods of increasing the metabolic activity in a mammal. The invention provides a plasmid comprising two or more of (a) a nucleic acid sequence encoding islet amyloid polypeptide (IAPP), (b) a nucleic acid sequence encoding leptin (LEP), and (c) a nucleic acid sequence encoding fibronectin type III domain containing 5 (FNDC5).

55. 发明申请

US20200239536A1 CYCLIC GALANIN-ANALOGS AND USES THEREOF 审中-公开
公开(公告)号：US20200239536A1
公开(公告)日：2020-07-30
申请号：US16665806
申请日：2019-10-28
申请人： LanthioPep B.V.
发明人： Anneke KUIPERS
IPC分类号： C07K14/575 , C07K1/107 , C07K1/04 , A61K38/22 , A61K47/54
摘要： The invention generally relates to the field of medicine and pharmacology. More particularly, it relates to novel analogs of galanin, and the use thereof in therapy. Provided is a cyclic peptide analog of galanin, wherein the galanin analog comprises a (methyl)Lanthionine bridge and wherein the analog has the general formula “X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-X22-”, or a truncated variant thereof lacking X1 and/or up to 11 of the C-terminal residues, wherein two residues selected from the group consisting of X3, X4, X6, X7, X10 and X13-X19 together form a Lanthionine bridge of the structure Ala-S-Ala, or a methylLanthionine bridge of the structure Abu-S-Ala or Ala-S-Abu.

56. 发明授权

US10723777B2 Peptide having anti-obesity and anti-diabetes efficacy and use thereof 有权
公开(公告)号：US10723777B2
公开(公告)日：2020-07-28
申请号：US16343559
申请日：2017-03-29
申请人： CAREGEN CO., LTD.
发明人： Yong Ji Chung , Eun Mi Kim
IPC分类号： A61K38/08 , A61K38/00 , A61K38/30 , A61P3/00 , A61P3/04 , A61P3/06 , A61P3/10 , C07K7/06 , C07K14/575
摘要： The present disclosure relates to peptides exhibiting an anti-obesity effect by inhibiting fat accumulation and decomposing already accumulated fats as well as an outstanding anti-diabetes effect by effectively lowering blood sugar levels. The peptides that downregulate the expression of the adipogenic markers PPARγ, ACC and/or aP2, upregulate the expression of the lipolytic factors pHSL, AMPK-α1, CGI-58 and/or ATGL, and reduce sizes of adipocyte and levels of cholesterol in blood are described. The excellent activity and stability of the peptides described herein provides advantages in applications such as drugs and quasi-drug products.

57. 发明授权

US10704038B2 Therapeutic fusion proteins 有权
公开(公告)号：US10704038B2
公开(公告)日：2020-07-07
申请号：US16105203
申请日：2018-08-20
申请人： Ipsen Bioinnovation Limited
发明人： John Chaddock , Elaine Harper
IPC分类号： C12N9/12 , C12N9/88 , C12N1/20 , C12N15/00 , C12P21/04 , C12P21/06 , C07H21/04 , A61K38/43 , C07K1/00 , C12N9/96 , C07K7/18 , C07K7/23 , C07K14/575 , C12N9/52 , C12N15/62 , C07K14/60 , C12N9/50 , A61K38/00
摘要： The present invention relates to the construction of a new class of Targeted Secretion Inhibitors (TSIs), which comprise a non-cytotoxic protease, translocation peptide and a targeting moiety peptide, wherein the targeting moiety peptide has a free N-terminal domain and a free C-terminal domain; to a single-chain fusion protein precursor thereof, and to a method of activating said single-chain fusion protein precursor.

58. 发明授权

US10583172B2 HPYY(1-36) having a beta-homoarginine substitution at position 35 有权
公开(公告)号：US10583172B2
公开(公告)日：2020-03-10
申请号：US15036509
申请日：2014-11-13
申请人： Novo Nordisk A/S
发明人： Soeren Oestergaard , Kilian Waldemar Conde Frieboes , Birgit Wieczorek , Jens Kaalby Thomsen , Birgitte Schjellerup Wulff
IPC分类号： C07K14/575 , A61K38/00 , A61K38/22 , A61K47/54
摘要： The invention relates to PYY compounds having the amino acid in the position corresponding to position 35 of hPYY(1-36) substituted with beta-homoarginine and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.

59. 发明授权

US10550168B2 Composition for treating diabetes or diabesity comprising oxyntomodulin analog 有权
公开(公告)号：US10550168B2
公开(公告)日：2020-02-04
申请号：US15960205
申请日：2018-04-23
申请人： HANMI PHARM. CO., LTD.
发明人： Jin Sun Kim , Dae Jin Kim , Sang Hyun Lee , Sung Youb Jung , Se Chang Kwon
IPC分类号： A61K38/22 , A61K38/26 , C07K14/575 , C07K14/605 , C07K16/00 , C07K16/30 , A61K47/64
摘要： Disclosed are a composition for preventing or treating diabetes, disbesity or diabetic complications, containing an oxyntomodulin analog as an active ingredient and a method for treating diabetes, diabesity or diabetic complications, including administering a pharmaceutically effective amount of an oxyntomodulin analog to a subject. The oxyntomodulin analog shows a greater activity to activate a GLP-1 receptor and a glucagon receptor, than native oxyntomodulin. The oxyntomodulin analog induces an expansion of beta-cells and increases insulin secretion, thereby reducing blood glucose levels that were increased due to a high-calorie and high-fat diet. The oxyntomodulin analog induces decreases in a body weight and appetite to improve insulin sensitivity and is useful in maintaining normal blood glucose levels.

60. 发明申请

US20200010523A1 Chimera of Bone Morphogenic Protein 2 and the Mullerian-Inhibiting Substance Type II Receptor Binding Region of Mullerian-Inhibiting Substance 审中-公开
公开(公告)号：US20200010523A1
公开(公告)日：2020-01-09
申请号：US16483944
申请日：2018-02-12
申请人： INSTITUTE FOR CANCER RESEARCH d/b/a THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER
发明人： Roland L. Dunbrack , Jared Adolf-Bryfogle , Gregory P. Adams , Matthew K. Robinson
IPC分类号： C07K14/51 , C07K14/575 , A61K45/06 , A61K38/18 , A61K38/22
摘要： Recombinant proteins that comprise a bone morphogenic protein 2 backbone onto which was grafted a Müllerian-inhibiting substance type II receptor binding region of the Müllerian-inhibiting substance protein are provided. These proteins bind to this receptor on the surface of epithelial cancer cells, and induce apoptosis of such cells. These proteins are useful, for example, in the treatment of cancers such as ovarian, uterine, endometrial, fallopian tube, breast, prostate, and lung cancers.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式